Diligence memo · auto-generated · as of July 2, 2026
Arix Bioscience plc
Arix Bioscience plc has raised $39M over 2 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Arix Bioscience plc operates in Biotech, based in LONDON.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Arix Bioscience plc has raised $39M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $21M on 2018-03-20.
Most recent recorded round closed around 2018-03-20.
Valuation (modeled)modeled
Provath models Arix Bioscience plc at approximately $851M (range $43M–$3.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 8.3 yr ago; this sector typically re-raises about every 11 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 96% of Biotech peers (233 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Lygos, Inc., Yield10 Bioscience, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.